Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Nab-Paclitaxel PIPAC paclitaxellel és ramucirumabbal kombinációban hashártya-áttétekkel járó gyomorrák kezelésére

2026. november 6. frissítette: City of Hope Medical Center

A Nab-Paclitaxel PIPAC (nyomásos intraperitoneális aeroszolos kemoterápia) 1. fázisú vizsgálata peritoneális metasztázisokkal járó gyomorrák másodvonalbeli terápiájával kombinálva

This phase I trial tests the safety, side effects and best dose of nab-paclitaxel pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in combination with second-line chemotherapy, paclitaxel and ramucirumab, and tests how well they work in treating stomach cancer that has spread from where it first started to the tissue that lines the abdominal wall and organs (peritoneal metastases). Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. PIPAC delivers chemotherapy, such as nab-paclitaxel, that has been turned into a fine mist (aerosolized) at a high pressure directly into the abdominal cavity. Aerosolized chemotherapy delivered directly into the peritoneal space has been shown to deliver higher drug concentrations to the tumor. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab may be safe, tolerable, and/or effective in treating gastric cancer patients with peritoneal metastases.

A tanulmány áttekintése

Részletes leírás

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of nab-paclitaxel PIPAC when given in combination with standard-of-care second-line systemic therapy (paclitaxel, ramucirumab).

II. To assess the safety and tolerability of nab-paclitaxel PIPAC plus systemic paclitaxel and ramucirumab, and accompanying dose modification plan, by evaluation of toxicities including: type, frequency, severity, attribution, time course and duration.

SECONDARY OBJECTIVES:

I. To evaluate the anti-tumor activity of nab-paclitaxel when given in combination with standard-of-care second-line systemic therapy (paclitaxel, ramucirumab), as assessed by:

Ia. Response Evaluation Criteria in Solid Tumors (RECIST), if available, version 1.1 via computed tomography (CT) scan at baseline and every 8 weeks until disease progression; Ib. Peritoneal Regression Grading Score (PRGS) via biopsy at each PIPAC cycle (both pre-PIPAC and post-PIPAC peritoneal samples will be obtained); Ic. Peritoneal Carcinomatosis Index (PCI) at the time of laparoscopy; and Id. Overall survival (OS) and progression-free survival (PFS) estimates at 6-months, 1-year and 2-years.

II. To estimate the PIPAC technical failure rate. III. To characterize and evaluate peritoneal tumor associated complications. IV. To characterize and evaluate post-operative surgical complications by Clavien-Dindo classification evaluated at 30 days after each PIPAC technical failure rate.

V. To evaluate patient-reported health state/quality of life and symptoms before treatment and at 6, 12, 18, and 24 weeks/off study, as measured by the European Quality of Life Five Dimension Five Level Scale (EQ-5D-5L) and MD Anderson Symptom Inventory (MDASI).

EXPLORATORY OBJECTIVES:

I. Characterize the peritoneal tumor and immune tumor microenvironment changes in response to therapy.

II. Evaluate the pharmacokinetics of nab-paclitaxel PIPAC. III. Evaluate patients' quality of life during nab-paclitaxel PIPAC plus systemic therapy.

OUTLINE: This is a dose-escalation study of nab-paclitaxel PIPAC in combination with paclitaxel and ramucirumab followed by a dose-expansion study.

Patients receive nab-paclitaxel PIPAC intraperitoneally (IP) over 40 minutes on day 1 and standard of care (SOC) paclitaxel intravenously (IV) over 60 minutes on days 15, 22, 29, 43, and 50 and ramucirumab IV over 30-60 minutes on days 15, 29 and 43 of each cycle. Cycles repeat every 8 weeks (56 days) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may then continue SOC paclitaxel IV on days 1, 8, and 15 and ramucirumab IV on days 1 and 15 of each cycle per physician as deemed appropriate. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, tumor biopsy, and CT or magnetic resonance imaging (MRI) throughout the study.

After completion of study treatment, patients are followed up at 4 weeks, then every 3 months for year 1 followed by every 6 months until progression or initiation of a new systemic anti-cancer therapy or death, whichever occurs first.

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

30

Fázis

  • 1. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

    • California
      • Duarte, California, Egyesült Államok, 91010
        • Toborzás
        • City of Hope Medical Center
        • Kutatásvezető:
          • Yanghee Woo
        • Kapcsolatba lépni:

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

18 év és régebbi (Felnőtt, Idősebb felnőtt)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Patients must have failed first-line systemic therapy (fluorouracil, leucovorin calcium, oxaliplatin [FOLFOX] with or without immunotherapy, or other fluoropyrimidine and platinum-based therapy)

    • Prior immunotherapy allowed
    • Up to 4 cycles of second-line therapy allowed if no progression is documented
  • Documented informed consent of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: ≥ 18 years

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

  • Histologically or cytologically confirmed gastric adenocarcinoma

  • Visible peritoneal metastatic disease on cross-sectional imaging or diagnostic laparoscopy (does not have to be measurable by RECIST 1.1)

  • Fully recovered from acute toxic effects (except alopecia, hearing loss, or non-clinically significant laboratory abnormalities) ≤ grade 1 of prior anti-cancer therapy

  • The patient's urinary protein is ≤ 1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥ 2+, then a 24-hour urine must be collected and must demonstrate < 1000mg protein in 24 hours

  • Complete medical history and physical exam (within 28 days prior to day 1 of protocol therapy)

  • Absolute neutrophil count (ANC) ≥ 1,500/mcL (within 28 days prior to day 1 of protocol therapy)

  • Platelets ≥ 100,000/mcL (within 28 days prior to day 1 of protocol therapy)

  • Hemoglobin ≥ 8 g/dL (within 28 days prior to day 1 of protocol therapy)

  • Serum albumin ≥ 2.8 g/dL (within 28 days prior to day 1 of protocol therapy)

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless has Gilbert's disease, then direct bilirubin < 1.5 mg/dL) (within 28 days prior to day 1 of protocol therapy)

  • Aspartate aminotransferase (AST) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)

  • Alanine aminotransferase (ALT) ≤ 5 x ULN (within 28 days prior to day 1 of protocol therapy)

  • International normalized ratio (INR) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)

  • Prothrombin time (PT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)

  • Partial thromboplastin time (PTT) ≤ 1.5 x ULN (within 28 days prior to day 1 of protocol therapy)

  • Calculated creatinine clearance of ≥ 45 mL/min per 24 hour urine test or the Cockcroft-Gault formula (within 28 days prior to day 1 of protocol therapy)

  • Seronegative for HIV antigen (Ag)/antibody (Ab) combo (within 28 days prior to day 1 of protocol therapy)

    • If seropositive, patient may be eligible if they are stable on antiretroviral therapy, have a CD4 T cell count ≥ 200/µL, and have an undetectable viral load
  • Documented virology status of hepatitis, confirmed by hepatitis B virus (HBV) and hepatitis C virus (HCV) tests (within 28 days prior to day 1 of protocol therapy)

    • For patients with active HBV, HBV deoxyribonucleic acid (DNA) < 500 IU/mL during screening, initiation of anti-HBV treatment at least 14 days prior to day 1 of cycle 1, and willingness to continue anti-HBV treatment during the study (per standard of care)
    • If seropositive for HCV, nucleic acid quantification must be performed. Viral load must be undetectable
  • WOMEN OF CHILDBEARING POTENTIAL (WOCBP): Negative urine or serum pregnancy test (within 28 days prior to day 1 of protocol therapy)

    • If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  • Agreement by females and males of childbearing potential to use an effective method of birth control (e.g., licensed hormonal/barrier methods or surgery intended to prevent pregnancy [or with a side effect of pregnancy prevention]) or abstain from heterosexual activity for the course of the study through at least 14 months after the last dose of protocol therapy.

    • Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for > 1 year (women only)

Exclusion Criteria:

  • Intolerance to taxanes

  • Bowel obstruction requiring exclusive total parenteral nutrition

  • Any history of, or current, brain or subdural metastases

  • Life expectancy < 3 months

  • Treatment with therapeutic oral or IV antibiotics within 14 days prior to day 1 cycle 1 of treatment

    • Patients receiving prophylactic antibiotics are eligible, provided the signs of active infection have resolved
  • Any prior malignancy except adequately treated basal or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for two years

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents (taxanes, etc.)

  • Clinically significant uncontrolled illness such as uncontrolled hypertension (HTN)

  • History of arterial thromboembolic events such as myocardial infarction (MI), cerebrovascular accident (CVA)

  • History of gastrointestinal (GI) perforation

  • FEMALES ONLY: Pregnant or breastfeeding

  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures

  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: N/A
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Treatment (nab-paclitaxel PIPAC, paclitaxel, ramucirumab)

Patients receive nab-paclitaxel PIPAC IP over 40 minutes on day 1 and SOC paclitaxel IV over 60 minutes on days 15, 22, 29, 43, and 50 and ramucirumab IV over 30-60 minutes on days 15, 29 and 43 of each cycle. Cycles repeat every 8 weeks (56 days) for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients may then continue SOC paclitaxel IV on days 1, 8, and 15 and ramucirumab IV on days 1 and 15 of each cycle per physician as deemed appropriate. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, tumor biopsy, and CT or MRI throughout the study.

Given IV

Más nevek:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Undergo blood sample collection

Más nevek:
  • Biológiai mintagyűjtés
  • Biominta összegyűjtve
  • Mintagyűjtemény

Undergo tumor biopsy

Más nevek:
  • Bx
  • BIOPSY_TYPE

Undergo CT

Más nevek:
  • CT
  • MACSKA
  • CAT Scan
  • Számítógépes axiális tomográfia
  • Számítógépes tomográfia
  • CT vizsgálat
  • tomográfia
  • Számítógépes axiális tomográfia (eljárás)
  • Számítógépes tomográfia (CT) vizsgálat

Undergo MRI

Más nevek:
  • MRI
  • Mágneses rezonancia
  • Mágneses rezonancia képalkotás
  • Orvosi képalkotás, mágneses rezonancia / nukleáris mágneses rezonancia
  • ÚR
  • MR képalkotás
  • MRI vizsgálat
  • NMR képalkotás
  • NMRI
  • Mágneses magrezonancia képalkotás
  • Mágneses rezonancia képalkotás (MRI)
  • sMRI
  • Mágneses rezonancia képalkotás (eljárás)
  • MRI-k
  • Strukturális MRI

Ancillary studies

Given IV

Más nevek:
  • LY3009806
  • LY 3009806
  • IMC-1121B
  • Cyramza
  • Anti-VEGFR-2 teljesen humán monoklonális antitest IMC-1121B
  • Monoklonális antitest HGS-ETR2
  • IMC 1121B
  • IMC1121B
  • LY-3009806

Given PIPAC

Given IP

Más nevek:
  • ABI-007
  • Abraxane
  • Albuminhoz kötött paklitaxel
  • ABI 007
  • Albumin-stabilizált nanorészecskés paclitaxel
  • Nanorészecske Albuminhoz kötött paklitaxel
  • Nanorészecske paclitaxel
  • Paclitaxel albumin
  • paklitaxel albuminnal stabilizált nanorészecske készítmény
  • Fehérjéhez kötött paklitaxel
  • ABI007
  • Paclitaxel Protein-Bound
  • Paclitaxel nanopartikulum albuminhoz kötött
  • Naveruclif

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Dose-limiting toxicity (DLT)
Időkeret: Up to 6 weeks after the first pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment

Will be evaluated and graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Toxicities will be summarized by type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment, and reversibility or outcome. Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated.

Up to 6 weeks after the first pressurized intraperitoneal aerosolized chemotherapy (PIPAC) treatment

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Incidence of treatment-related adverse events (AEs)
Időkeret: Up to 4 weeks after last dose of nab-paclitaxel

Will be evaluated and graded based on NCI CTCAE v 5.0. The number and percent of patients with AEs will be tabulated by system organ class and preferred term using the Medical Dictionary for Regulatory Activities preferred term dictionary. The tabulations will be generated so that the number and percent of patients with events in each severity, relatedness, and serious category can be obtained for each preferred term. Listings and narratives will be provided for deaths on study, serious AEs, DLTs, and events leading to discontinuation of treatment.

Up to 4 weeks after last dose of nab-paclitaxel
Incidence of post-operative surgical complications
Időkeret: At 4 weeks post-PIPAC procedure

Will be evaluated using Clavien-Dindo classification. Results will be strictly descriptive in nature.

At 4 weeks post-PIPAC procedure
Objective response rate (ORR)
Időkeret: Up to 2 years

Will be evaluated according to Response Evaluation Criteria in Solid Tumors v 1.1. ORR will be defined as the percentage of evaluable patients who have achieved complete response (CR), partial response (PR), or stable disease (SD). Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated.

Up to 2 years
Peritoneal Carcinomatosis Index (PCI)
Időkeret: At time of laparoscopy

PCI will be defined as the percentage of evaluable patients who have achieved CR, PR, or SD. Confidence intervals for the true success proportion will be calculated according to the approach of Clopper and Pearson

At time of laparoscopy
Peritoneal Regression Grading Score (PRGS)
Időkeret: At baseline and post-PIPAC, assessed up to 2 years

PRGS will be defined as the percentage of evaluable patients who have achieved a decrease in the PRGS over successive biopsies. Confidence intervals for the true success proportion will be calculated according to the approach of Clopper and Pearson

At baseline and post-PIPAC, assessed up to 2 years
Progression-free survival (PFS)
Időkeret: From first PIPAC to progression of disease, assessed up to 2 years

PFS will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate.

From first PIPAC to progression of disease, assessed up to 2 years
Overall survival (OS)
Időkeret: From initiation of treatment to death or last contact, whichever occurs first up to 2 years

OS will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate.

From initiation of treatment to death or last contact, whichever occurs first up to 2 years
PIPAC technical failure rate
Időkeret: Up to 2 years

The technical failure rate will be calculated. The device malfunction rate will also be calculated. Rates and associated 95% Clopper and Pearson binomial confidence limits will be estimated.

Up to 2 years
Patient-reported health status and quality of life
Időkeret: At baseline and at 6, 12, 18 and 24 weeks off study

Will be measured using the European Quality of Life Five Dimension Five Level Scale and will be summarized with descriptive statistics.

At baseline and at 6, 12, 18 and 24 weeks off study
Patient-reported symptoms
Időkeret: At baseline and at 6, 12, 18 and 24 weeks off study

Will be measured using the MD Anderson Symptom Inventory and will be summarized with descriptive statistics.

At baseline and at 6, 12, 18 and 24 weeks off study
Time to peritoneal tumor associated complications
Időkeret: Up to 2 years

Will be estimated using the Kaplan-Meier estimator and 95% confidence intervals will be calculated using the logit transformation and the Greenwood variance estimate.

Up to 2 years
Functional status
Időkeret: Up to 1 year

Will be measured by the number of daily steps before and after treatments.

Up to 1 year

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Kutatásvezető: Yanghee Woo, City of Hope Medical Center

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2025. október 29.

Elsődleges befejezés (Becsült)

2029. január 14.

A tanulmány befejezése (Becsült)

2029. január 14.

Tanulmányi regisztráció dátumai

Először benyújtva

2024. november 4.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2024. november 4.

Első közzététel (Tényleges)

2024. november 5.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. november 10.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. november 6.

Utolsó ellenőrzés

2026. november 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel